J&J Enters HIV Arena With Prezista; Darunavir Is Tenth Protease Inhibitor
Executive Summary
The strength of darunavir's bond with protease may provide Johnson & Johnson/Tibotec's Prezista an advantage against other drugs in the class for treatment-experienced HIV patients
You may also be interested in...
J&J Growth Plan Calls For Four Virology Filings In As Many Years
Johnson & Johnson's next generation non-nucleoside reverse transcriptase inhibitor TMC 125 is on deck to be the first of the firm's four virology NDAs over the next four years, Group Chairman Julie McHugh said during an analyst update outlining the company's growth strategy in New Brunswick, N.J. June 7
J&J Growth Plan Calls For Four Virology Filings In As Many Years
Johnson & Johnson's next generation non-nucleoside reverse transcriptase inhibitor TMC 125 is on deck to be the first of the firm's four virology NDAs over the next four years, Group Chairman Julie McHugh said during an analyst update outlining the company's growth strategy in New Brunswick, N.J. June 7
NME Slump Continues: FDA Clears 18 Novel Drugs In 2006, Same As 2005
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals